文献速递头颈部肿瘤放疗姑息放疗与转移瘤

人乳头瘤病毒相关口咽癌放疗期间及之后患者报告症状严重程度、健康相关生活质量与情绪困扰轨迹:TROG 12.01二次分析

Patient-Reported Symptom Severity, Health-Related Quality of Life, and Emotional Distress Trajectories During and After Radiation Therapy for Human Papillomavirus-Associated Oropharyngeal Cancer: A TROG 12.01 Secondary Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-03-01

该研究为TROG 12.01临床试验的二次分析,纳入人乳头瘤病毒相关口咽鳞状细胞癌患者,采用潜类别增长混合模型识别放化疗前、中、后患者报告结局的轨迹。研究识别出症状严重程度、干扰、健康相关生活质量、焦虑和抑郁的潜在轨迹,所有轨迹在12个月后保持稳定。年龄、体能状态、教育程度、西妥昔单抗使用和基线焦虑在不同轨迹间存在差异。

要点

  • 识别出4条头颈癌症状严重程度轨迹,所有轨迹在12个月后保持稳定。
  • 参考轨迹HNSS4(n=74)基线0.1,峰值4.6,12个月降至0.6。
  • HNSS1(缓慢恢复,n=25)从急性峰值4.9恢复至12个月0.9。

核心结论

  • 潜类别增长混合模型识别出放化疗期间及之后不同的患者报告结局轨迹。
  • 这些轨迹及其与患者特征和治疗因素变异的关联,为识别可能需要在放化疗前、中、后增加支持的患者提供了临床相关见解。

研究设计与样本

  • 该研究为临床试验TROG 12.01的二次分析,涉及人乳头瘤病毒相关口咽鳞状细胞癌患者。
  • 采用MD Anderson症状量表-头颈、癌症治疗功能评估-通用和医院焦虑抑郁量表分别评估头颈癌症状严重程度和干扰、通用健康相关生活质量和情绪困扰。
  • 采用潜类别增长混合模型识别不同的潜在轨迹,并比较轨迹组间的基线和治疗变量。

主要发现

  • 潜类别增长混合模型为所有患者报告结局识别出潜在轨迹:头颈癌症状严重程度、头颈癌症状干扰、健康相关生活质量、焦虑和抑郁。
  • 识别出4条头颈癌症状严重程度轨迹(HNSS1-4),通过基线、治疗症状峰值期间以及早期和中期恢复期间的差异区分。
  • 所有轨迹在12个月后保持稳定。
  • 参考轨迹HNSS4(n=74)基线评分为0.1(95%CI,0.1-0.2),峰值4.6(95%CI,4.2-5.0),早期快速恢复(1.1;95%CI,0.8-2.2),逐渐改善至12个月(0.6;95%CI,0.5-0.8)。
  • HNSS2(高基线,n=30)患者基线评分较高(1.4;95%CI,0.8-2.0),其他方面与HNSS4相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This secondary analysis of clinical trial TROG 12.01, involving patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma, aimed to identify patient-reported outcome (PRO) trajectories before, during, and after chemoradiotherapy. METHODS AND MATERIALS: Head and neck cancer symptom severity (HNSS) and interference (HNSI), generic health-related quality of life (HRQL), and emotional distress were assessed with the MD Anderson Symptom Inventory-Head and Neck, Functional Assessment of Cancer Therapy-General, and Hospital Anxiety and Depression Scale questionnaires, respectively. Latent class growth mixture modeling (LCGMM) was used to identify distinct underlying trajectories. Baseline and treatment variables were compared between trajectory groups. RESULTS: The LCGMM identified latent trajectories for all PROs: HNSS, HNSI, HRQL, anxiety, and depression. Four HNSS trajectories (HNSS1-4) were identified, distinguished by differences in HNSS at baseline, during the peak of treatment symptoms, and during early and intermediate recovery. All trajectories were stable beyond 12 months. The reference trajectory (HNSS4, n = 74) score was 0.1 (95% confidence interval [CI], 0.1-0.2) at baseline, peaking at 4.6 (95% CI, 4.2-5.0), with rapid early recovery (1.1; 95% CI, 0.8-2.2) and gradual improvement to 12 months (0.6; 95% CI, 0.5-0.8). Patients in HNSS2 (high baseline, n = 30) reported higher baseline scores (1.4; 95% CI, 0.8-2.0) but were otherwise similar to HNSS4. Patients in HNSS3 (low acute, n = 53) reported reduced acute symptoms (2.5; 95% CI, 2.2-2.9) with stable scores beyond 9 weeks after chemoradiotherapy (1.1; 95% CI, 0.9-1.4). Patients in HNSS1 (slow recovery, n = 25) had slower recovery from an acute peak of 4.9 (95% CI, 4.3-5.6) to 0.9 (95% CI, 0.6-1.3) at 12 months. Age, performance status, education, receipt of cetuximab, and baseline anxiety varied between trajectories. The other PRO models demonstrated clinically relevant trajectories, with distinct associations with baseline factors. CONCLUSIONS: LCGMM identified distinct PRO trajectories during and after chemoradiotherapy. These and their associations with variations in the characteristics and treatment factors of patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma provide clinically relevant insights into identifying patients who may require increased support before, during, or after chemoradiotherapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. McDowell L, Bressel M, King MT, et al. Patient-Reported Symptom Severity, Health-Related Quality of Life, and Emotional Distress Trajectories During and After Radiation Therapy for Human Papillomavirus-Associated Oropharyngeal Cancer: A TROG 12.01 Secondary Analysis. Int J Radiat Oncol Biol Phys. 2023. PMID: 36868523. doi:10.1016/j.ijrobp.2023.02.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。